Private Equity

PE-VC Fund Investments

Regenerative medicine-focused biotech co. Pandorum raises $18-M

Business Line  

Bengaluru-headquartered Pandorum has raised USD 18 million in a Series B funding round. The round was led by Protons Corporate, with participation from existing investor Ashish Kacholia, Avinya Fund and the Burman Family as well as Galentic Pharma and Noblevast Advisory. Bandana Kankani advised the transaction.Founded by Tuhin Bhowmick and Arun Chandru, Pandorum develops exosome-based therapies designed to modify disease processes by reprogramming tissue responses such as inflammation and fibrosis. The company plans to use the new funds to support clinical programs, manufacturing scale-up, and operations across the USA, Japan, and the Middle East. The firm is also expanding its platform to address inflammatory and degenerative conditions affecting the lung, liver, and nervous system.

Between Feb 2018 and Nov 2025, Pandorum Technologies had attracted about USD 43 M from Ashish Kacholia, Hero Enterprises, IAN Fund, KITVEN, Kotak Alternate, Xeed Ventures and others.